Patents Represented by Attorney Kenneth F. Mitchell

Find this attorney in the Justia Lawyer Directory

  • N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses
    Patent number: 8299246
    Abstract: The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: October 30, 2012
    Assignee: AstraZeneca AB
    Inventors: Stephen Brough, Richard Evans, Timothy Jon Luker, Piotr Raubo
  • Dihydropyridopyrimidines for the treatment of AB-related pathologies
    Patent number: 8188101
    Abstract: Dihydropyridopyrimidine compounds of formula (Ia) and therapeutically acceptable salts thereof, wherein R1, R2 and Z are as defined in the specification; processes for making them and methods for using them in the treatment of A?-related pathologies.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: May 29, 2012
    Assignee: AstraZeneca AB
    Inventors: Rickard Forsblom, Kim Paulsen, Didier Rotticci, Ellen Santangelo, Magnus Waldman
  • Imidazole substituted pyrimidines
    Patent number: 8178529
    Abstract: Imidazole substituted pyrimidines and pharmaceutically acceptable salts thereof; pharmaceutical formulations containing such pyrimidines; the use of such compounds in therapy; the use of such compounds for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as methods of treatment of such disorders comprising administering to subjects in need of such treatment therapeutically effective amounts of such compounds.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: May 15, 2012
    Assignee: AstraZeneca AB
    Inventors: Per I Arvidsson, Jeremy Nicholas Burrows, Ulrika Yngve, Erica Tjerneld
  • Dibenzothiazepine derivatives and uses thereof—424
    Patent number: 8158618
    Abstract: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: April 17, 2012
    Assignee: AstraZeneca AB
    Inventors: Dean Brown, James R. Damewood, Phil Edwards, James Hulsizer, James Campbell Muir, M. Edward Pierson, Jr., Ashokkumar Bhikkappa Shenvi, Steven Wesolowski, Dan Widzowski, Michael Wood
  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 8153638
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286
    Patent number: 8148372
    Abstract: Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Joseph Cacciola, James Empfield, James Folmer, Angela M Hunter, Scott Throner
  • Polymorph of N,N-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt
    Patent number: 8148406
    Abstract: Polymorphs of N,N-diethyl-4-(3-fluorophenyl-piperidin-4-ylidene-methyl)-benzamide hydrochloride salt, methods of making these polymorphs and uses thereof are described.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 3, 2012
    Assignee: AstraZeneca AB
    Inventors: Simon Nicholas Black, Steve Cook, Louis Joseph Diorazio, James Hulsizer, Gary Moore, Kathryn Quigley
  • N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
    Patent number: 8143408
    Abstract: The present invention relates to new compounds of formula (I) and to pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof.
    Type: Grant
    Filed: April 22, 2008
    Date of Patent: March 27, 2012
    Assignee: AstraZeneca AB
    Inventors: Yevgeni Besidski, Inger Kers, Martin Nylöf, Lars Sandberg, Karin Skogholm
  • Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
    Patent number: 8129393
    Abstract: Compounds of general formula: as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain, depression and anxiety.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: William Brown, Andrew Griffin, Thomas Hudzik, Carla Maciag, Gennady Smagin, Christopher Walpole
  • Process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-indole-5-carbonitrile 701
    Patent number: 8101750
    Abstract: The present invention relates to a new process for the manufacture of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base and pharmaceutically acceptable salts thereof, particularly the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, and to new intermediates prepared in said process suitable for large scale manufacturing of said compound.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: January 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Vern Delisser, Martin Hedberg, Annette Jansson, Andreas Rådevik, Per Ryberg, Swantje Thiering
  • Alkylsulphonamide quinolines
    Patent number: 8071621
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: December 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Thomas Simpson, James Kang, Jeffrey Albert, Cristobal Alhambra, Gerard Koether, James Woods, Yan Li
  • Cyclopropyl amide derivatives
    Patent number: 8063215
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: November 22, 2011
    Assignee: AstraZeneca AB
    Inventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • Ethanamine compounds and methods of using the same 545
    Patent number: 8013165
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P McCauley, Lihong Shen, David Nugiel
  • Citrate salt of an indole derivative and its pharmaceutical use
    Patent number: 8008294
    Abstract: The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: August 30, 2011
    Assignee: AstraZeneca AB
    Inventors: Tesfai Sebhatu, Erica Ståhle
  • Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7968570
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: June 28, 2011
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic glutamate receptor isoxazole ligands and their use as potentiators
    Patent number: 7888353
    Abstract: Compounds in accord with Formula I: wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: February 15, 2011
    Assignee: AstraZeneca AB
    Inventors: Joseph Cacciola, James Empfield, James Folmer, Angela M Hunter, Scott Throner
  • Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
    Patent number: 7868008
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: January 11, 2011
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7816354
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: October 19, 2010
    Assignee: AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma, Babu Joseph, Joshua Clayton, Krzysztof Swierczek
  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 7807706
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: October 5, 2010
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841
    Patent number: 7799792
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 21, 2010
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi